Vascular Protection in Diabetic Stroke: Role of Matrix Metalloprotease-Dependent Vascular Remodeling

[1]  入江 潤一郎,et al.  Glucose control and vascular complications in veterans with type 2 diabetes , 2009 .

[2]  A. Ergul,et al.  Adaptive Cerebral Neovascularization in a Model of Type 2 Diabetes , 2009, Diabetes.

[3]  E. Kilpatrick,et al.  Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control , 2009, International journal of clinical practice.

[4]  K. Norga,et al.  Expanding roles for AMP‐activated protein kinase in neuronal survival and autophagy , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[5]  G. Dhar.  Intensive glycemic control: implications of the accord, advance, and VADT trials for family physicians. , 2009, Canadian family physician Medecin de famille canadien.

[6]  H. Elewa,et al.  Early Atorvastatin Reduces Hemorrhage after Acute Cerebral Ischemia in Diabetic Rats , 2009, Journal of Pharmacology and Experimental Therapeutics.

[7]  D. Federman,et al.  Implications of New Diabetes Treatment Trials: Should Current Clinical Practice be Altered? , 2009, Postgraduate medicine.

[8]  H. Schatz.  [2008--The year of the big studies about the therapy of type-2-diabetes. ACCORD, ADVANCE, VADT, and the UKPDS 10-year follow-up data]. , 2009, MMW, Fortschritte der Medizin.

[9]  L. McCullough,et al.  Sex Differences in Minocycline-Induced Neuroprotection after Experimental Stroke , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  A. Dorrance,et al.  Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[11]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[12]  B. Howard,et al.  Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials , 2009, Diabetes Care.

[13]  H. Lebovitz.  Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance. , 2008, Journal of the Indian Medical Association.

[14]  H. Elewa,et al.  Vascular Protection with Candesartan after Experimental Acute Stroke in Hypertensive Rats: A Dose-Response Study , 2008, Journal of Pharmacology and Experimental Therapeutics.

[15]  S. Correia,et al.  Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. , 2008, Medicinal chemistry (Shariqah (United Arab Emirates)).

[16]  L. Gnudi,et al.  ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  E. Lo,et al.  A new penumbra: transitioning from injury into repair after stroke , 2008, Nature Medicine.

[18]  Askiel Bruno,et al.  Treatment of Hyperglycemia In Ischemic Stroke (THIS): A Randomized Pilot Trial , 2008, Stroke.

[19]  M. Grant,et al.  Myogenic tone and reactivity of cerebral arteries in type II diabetic BBZDR/Wor rat. , 2008, European journal of pharmacology.

[20]  Sumit R. Majumdar,et al.  Admission Hyperglycemia Predicts a Worse Outcome in Stroke Patients Treated With Intravenous Thrombolysis , 2008, Diabetes Care.

[21]  J. Switzer,et al.  Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes , 2007, BMC neurology.

[22]  A. Dorrance,et al.  Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[23]  Yiqian Zhu,et al.  Matrix Metalloproteinase-9 Inhibition Attenuates Vascular Endothelial Growth Factor-Induced Intracerebral Hemorrhage , 2007, Stroke.

[24]  D. Goff,et al.  Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. , 2007, The American journal of cardiology.

[25]  D. Pomp,et al.  Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains. , 2007, Physiological genomics.

[26]  V. Perkovic,et al.  ADVANCE: breaking new ground in type 2 diabetes , 2006, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[27]  D. Hess,et al.  Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke , 2006, BMC Neuroscience.

[28]  Thomas Krucker,et al.  New polyurethane‐based material for vascular corrosion casting with improved physical and imaging characteristics , 2006, Microscopy research and technique.

[29]  I. Idris,et al.  Diabetes mellitus and stroke , 2005, International journal of clinical practice.

[30]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[31]  Giuseppe Pennisi,et al.  Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease , 2005, Vascular medicine.

[32]  J. Arenillas,et al.  Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage: Relationship to Clinical and Radiological Outcome , 2004, Stroke.

[33]  E. Schiffrin,et al.  Persistent Remodeling of Resistance Arteries in Type 2 Diabetic Patients on Antihypertensive Treatment , 2004, Hypertension.

[34]  R. Knight,et al.  Single slice method for quantification of hemorrhagic transformation using direct ELISA , 2004, Neurological research.

[35]  P. Chan,et al.  A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Mulvany,et al.  The myogenic response: established facts and attractive hypotheses. , 1999, Clinical science.

[37]  M. Nelson,et al.  Increased myogenic tone and diminished responsiveness to ATP-sensitive K+ channel openers in cerebral arteries from diabetic rats. , 1997, Circulation research.

[38]  M. Cipolla,et al.  High glucose concentrations dilate cerebral arteries and diminish myogenic tone through an endothelial mechanism. , 1997, Stroke.

[39]  R. Myers,et al.  Hemorrhagic infarct conversion in experimental stroke. , 1992, Annals of emergency medicine.

[40]  M. Zimowska,et al.  [Structure and function of matrix metalloproteinases]. , 2009, Postepy biochemii.

[41]  P. Weinstein,et al.  Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.

[42]  K. Gabbay,et al.  Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. , 1975, Annual review of medicine.